Deal Announcements

Garnet Biotherapeutics Reels In Venture Capital Funding

Friday, January 30, 2009 5:38:00 AM PDT | VentureDeal Staff

Malvern, Pennsylvania  --  Biotechnology company Garnet Biotherapeutics has secured $10.4 million in new venture capital investment.

Garnet has developed technology to expand bone marrow derived cells that may help patients accelerate healing and reduce scarring from injuries.

SCP Partners led the round, which included Safeguard Scientifics and Alliance Technology Ventures. The company said it would use the funding for its Phase II clinical trials.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1